Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

basal insulin

Roche Basel Switzerland

Roche maintains top place in biologic sales

But the looming threat of biosimilars is set to shake up the market

- PMLiVE

Saxenda debuts in US with $1,000-a-month price tag

It is the first market for Novo Nordisk’s obesity therapy

- PMLiVE

Novo Nordisk opens insulin facility in Russia

It will focus on new modern insulin formulation and filling

- PMLiVE

FDA starts review of Novo’s refiled diabetes pair

Tresiba and Ryzodeg were rejected in 2013

- PMLiVE

Novo Nordisk will refile rejected diabetes duo in US

Danish firm hopes it will be second time lucky with key treatment

- PMLiVE

Novo Nordisk sheds autoimmune portfolio to BMS

Continues the trend of pharma buying up unwanted assets from rival firms

- PMLiVE

Novo’s Tresiba reduces risk of hypoglycaemia

New clinical data on the diabetes drug also shows blood glucose control benefits

- PMLiVE

Positive data in Saxenda diabetes prevention study

Drug found to improve blood glucose and blood pressure levels

- PMLiVE

Novo Nordisk’s oral GLP-1 analogue looks set for phase III

Semaglutide said to be one of the firm’s most promising prospects

- PMLiVE

Novo Nordisk confirms public listing for IT unit

Will spin off its NNIT business as a separate company

- PMLiVE

CHMP thumbs up for Novo’s obesity drug Saxenda

Diabetes drug liraglutide on course for new indication in EU

- PMLiVE

Is obesity really a problem in Brazil?

Obesity is on the rise in low- and middle-income countries, particularly in urban settings

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links